...
【24h】

Octreotide in the outpatient therapy of cirrhotic chylous ascites: a case report.

机译:奥曲肽在肝硬化乳糜性腹水的门诊治疗中:一例报告。

获取原文
获取原文并翻译 | 示例
           

摘要

Chylous ascites is a rare complication of liver cirrhosis associated with a poor short-term prognosis. We report the case of an 80-year-old male cirrhotic patient with refractory chylous ascites associated with portal hypertension. He was treated with total parenteral nutrition but chylous ascites relapsed at suspension. Patient was put on long-term subcutaneous octreotide (100 microg t.i.d.) as an outpatient. The treatment was well tolerated and led to clinical improvement, markedly reducing the need of total paracentesis and the amount of ascites. Octreotide was stopped after 6 months, and massive ascites did not relapse. After 1 year the patient was alive, with no need of paracentesis. Octreotide therapy should be considered in patients with cirrhosis and chylous ascites to simplify the outpatient management of the disease.
机译:乳状腹水是一种罕见的肝硬化并发症,伴有短期预后不良。我们报告一名难治性乳糜性腹水与门静脉高压症相关的80岁男性肝硬化患者的病例。他接受了全胃肠外营养治疗,但乳突性腹水在停药后复发。患者门诊长期服用皮下奥曲肽(100微克t.i.d.)该治疗耐受性良好,并导致临床改善,显着减少了全腹腔穿刺术的需要和腹水量。 6个月后停止使用奥曲肽,并且大量腹水没有复发。一年后,患者还活着,无需穿刺手术。肝硬化和乳糜性腹水的患者应考虑使用奥曲肽治疗,以简化疾病的门诊治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号